Biocon forced to move clinical trials out of India

Biocon, which sought to develop drugs for India and other emerging markets from home, is in a quandary. As the Indian authorities clamp on clinical trials, Biocon has been forced to move various Indian projects to the US and Europe. The move not only makes the process more cumbersome but results in a 10- to 20-fold increase in the cost of drug development for the Bangalore-based publicly-held company.

Read Full Story>>